Evidence map›Paper›PMID 40676153›Full record

ArticleCommunications biology2025

Characterization of an unusual SARS-CoV-2 main protease natural variant exhibiting resistance to nirmatrelvir and ensitrelvir.

Dipendra Bhandari, Oksana Gerlits, Stephen Keable, Leighton Coates, Annie Aniana, Rodolfo Ghirlando, Nashaat T Nashed, Andrey Kovalevsky, John M Louis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dipendra BhandariNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
Oksana GerlitsDepartment of Natural Sciences, Tennessee Wesleyan University, Athens, TN, USA.
Stephen KeableNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA.
Leighton CoatesSecond Target Station, Oak Ridge National Laboratory, Oak Ridge, TN, USA.ORCID http://orcid.org/0000-0003-2342-049X
Annie AnianaLaboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD, USA.
Rodolfo GhirlandoLaboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4880-4959
Nashaat T NashedLaboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5956-9475
Andrey KovalevskyNeutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA. kovalevskyay@ornl.gov.ORCID http://orcid.org/0000-0003-4459-9142
John M LouisLaboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD, USA. johnl@niddk.nih.gov.ORCID http://orcid.org/0000-0002-0052-1899

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DK075166-01
6 · The paper itself

Abstract

We investigate the effects of two naturally selected substitution and deletion (Δ) mutations, constituting part of the substrate binding subsites S2 and S4, on the structure, function, and inhibition of SARS CoV-2 main protease. Comparable to wild-type, MPro

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesDrug Resistance, ViralSARS-CoV-2COVID-19 Drug TreatmentHumansIndazolesLactamsLeucineMutationNitrilesProlineProtein ConformationTriazinesTriazolesAntiviral AgentsCoronavirus 3C ProteasesensitrelvirIndazolesLactamsLeucinenirmatrelvirNitrilesProlineTriazinesTriazoles

Identifiers

PMID40676153
PMCPMC12271536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.